293758-67-5

Basic information

• Product Name: 5-Nitro-3-phenyl-1H-indazole
• Synonyms: 5-Nitro-3-phenyl-1H-indazole
• CAS NO: 293758-67-5
• Molecular Formula: C₁₃H₉N₃O₂
• Molecular Weight: 239.22946
• Mol File: 293758-67-5.mol

Chemical Properties

• Boiling Point: 491.8 °C at 760 mmHg
• Flash Point: 251.2 °C
• Appearance: /
• Density: 1.389 g/cm³
• Vapor Pressure: 2.44E-09mmHg at 25°C
• Refractive Index: 1.716
• CAS DataBase Reference: 5-Nitro-3-phenyl-1H-indazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Nitro-3-phenyl-1H-indazole(293758-67-5)
• EPA Substance Registry System: 5-Nitro-3-phenyl-1H-indazole(293758-67-5)

Safety Data

• Hazardous Substances Data: 293758-67-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
5-Nitro-3-phenyl-1H-indazole is utilized as an intermediate in the synthesis of various pharmaceuticals and organic compounds. Its unique structure and properties allow for the development of new drugs with potential therapeutic applications.
Used in Antimicrobial Applications:
5-Nitro-3-phenyl-1H-indazole has been studied for its antimicrobial properties, making it a potential candidate for use in the development of new antimicrobial agents to combat resistant bacteria and other pathogens.
Used in Antitumor Applications:
5-Nitro-3-phenyl-1H-indazole has shown potential antitumor properties, indicating its use in the development of novel anticancer drugs. It may target specific cancer cells or pathways, offering a new approach to cancer treatment.
Used in Materials Science:
Due to its unique chemical and electronic properties, 5-Nitro-3-phenyl-1H-indazole may have applications in the field of materials science, potentially contributing to the development of new materials with specific properties for various industries.
Used in Organic Electronics:
5-Nitro-3-phenyl-1H-indazole's electronic properties also suggest potential applications in the field of organic electronics, where it could be used in the development of organic semiconductors, sensors, or other electronic devices.

InChI:InChI=1/C13H9N3O2/c17-16(18)10-6-7-12-11(8-10)13(15-14-12)9-4-2-1-3-5-9/h1-8H,(H,14,15)

Upstream product

• 34052-37-4 2-chloro-5-nitrobenzophenone 
• 5401-94-5 5-nitroindazole 
• 100-25-4 para-dinitrobenzene 
• 1666-17-7 benzaldehyde p-toluenesulfonylhydrazone 
• 183110-88-5 2-bromo-5-nitro-benzophenone 

Downstream Products

• 395099-05-5 3-phenyl-1H-indazol-5-amine 
• 599183-30-9 N-tert-Butoxycarbonyl-5-nitro-3-phenyl-1H-indazole 
• 13097-01-3 3-phenyl-1H-indazole 

Relevant articles and documents

INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

Synthesis of 1H-indazoles from N-tosylhydrazones and nitroaromatic compounds

A new method for the synthesis of 1H-indazoles from readily available N-tosylhydrazones and nitroaromatic compounds has been developed. This transformation occurs under transition-metal-free conditions and shows a wide substrate scope. The method has been

Indazole compounds, compositions thereof and methods of treatment therewith

This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

Methods for treating an inflammatory condition or inhibiting JNK

This invention is generally directed to Indazole Derivatives having the following structure: 1 or pharmaceutically acceptable salt thereof, wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Indazole derivatives as JNK inhibitors and compositions and methods related thereto

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation

Indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating, e.g., kinases-dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.